CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis

Detalhes bibliográficos
Principais autores:	Gelfand, JM, Abboud, H, Irani, SR, Nakajima, H, Piquet, A, Pittock, SJ, Yeh, EA, Overell, J, Rajan, S, El-Khairi, M, Lee, S-T
Formato:	Conference item
Idioma:	English
Publicado em:	Wiley 2022

Registros relacionados